Marijuana on the Mind:  
A Case Report of Adult Acute Persistent Cannabinoid Induced Psychosis  
Alexandria Plant¹; Kevin Peifer, DO²  
¹University of Connecticut School of Medicine, Farmington, CT  
²University of Connecticut, Anesthesiology Residency Program, Farmington, CT

INTRODUCTION

• The association between cannabis and psychosis is well documented, although exact neurological mechanisms remain unclear.
• Delta-9-tetrahydrocannabinol, or THC, is the psychoactive component.
• DSM-5 criteria includes Cannabis-Induced Psychotic Disorder (CIPD) under the Schizophrenia Spectrum and Other Psychotic Disorders.
• CIPD requires the presence of delusions and/or hallucinations during or soon after intoxication, symptoms not during delirium, significant distress or functional impairment, and must not be better explained by another etiology.
• For older adults, the management of chronic conditions and pain can pose a difficult challenge. Thus, medicinal marijuana has become a relevant topic in an effort to improve quality of life.
• Here we describe an interesting case of acute persistent cannabinoid induced psychosis in an adult secondary to medical marijuana use.

CASE PRESENTATION

• A 65 year old male with a history of fibromyalgia, anxiety, panic disorder, hypertension, and hyperlipidemia presented with altered mental status and was admitted for acute metabolic encephalopathy.
• He consumed edible cannabis on the day of admission and was found naked holding his genitalia while repeatedly saying “I just need to release.”
• One week prior, after ingesting cannabis, he locked himself in a bathroom for three days before a complete resolution of symptoms.
• Edibles and oils were obtained via a medical marijuana card for fibromyalgia the last few months.
• He was stable on Duloxetine and Clonazepam for many years for anxiety and panic disorder.
• Family history: psychosis in his paternal grandfather and undiagnosed psychiatric issues in his father.

HOSPITAL COURSE

• Day 5: Transferred to a psychiatric facility for psycho-education and psychotherapy in addition to Clonazepam and Olanzapine treatment.
• Day 14: Discharged home on Clonazepam and Olanzapine with improved manic symptoms. Plan to continue with intensive outpatient therapy.

DISCUSSION AND CONCLUSION

• This case illustrates the potential risks of medicinal marijuana in older adult populations, especially those with susceptibilities.
• It also highlights that while cannabinoid induced symptoms may improve, some may persist beyond intoxication with potentially lasting effects.
• In light of more widespread legalization of medicinal cannabis, this has great public health relevance.
• Additionally, it demonstrates the importance of identifying individuals more vulnerable to psychosis beyond that which has largely been described in developing or adolescent brains.

REFERENCES